日本东洋纺(Toyobo )斥巨资收购西班牙医疗器械生产商Spinreact
- Toyobo2013年8月15日 13:31 点击:3380
据日本共同社8月2日报道,日本东洋纺公司1日宣布,已成功收购西班牙医疗器械生产商Spinreact公司。收购目的是利用后者的销售网和工厂扩大海外销路。东洋纺斥资约30亿日元(约合人民币2亿元)收购了美国医疗器械销售公司美艾利尔集团持有的全部股份。
东洋纺在纺织以外还致力于拓展医疗和环境领域。公司预测未来以新兴市场国家为中心医疗诊断系统的市场将持续扩大。通过此次收购,公司计划5年后在该行业销售收入提升至约100亿日元。
Spinreact公司主营生产和销售中性脂肪检查等体检时使用的器械,在非洲和欧洲等90个国家拥有销售网。该公司2012财年销售收入约为30亿日元。
Toyobo Acquires Spain’s Spinreact S.A., a Global Manufacturer and Marketer of Diagnostic Reagents and Instruments ––Marking the Acceleration of Toyobo’s Overseas Expansion Strategy in Biotechnology––
Aug 1, 2013
Toyobo purchased 100% of the shares of Spinreact, S.A. (hereinafter, Spinreact), which manufactures in vitro diagnostic (IVD) reagents and instruments and markets these products through its global network. The purchase was completed on July 31, 2013, and all the shares were purchased from the corporate group of U.S. company Alere Inc. (NYSE: ALR). Following the acquisition of Spinreact, Toyobo will substantially accelerate its strategy of overseas expansion in the field of biotechnology.
1. Background of the Acquisition
Toyobo, as a company aiming to be “the category leader , continuing to create new value that contributes to society in the environment, life science, and high-function products fields,” has set the objectives of being a “strong company” that can grow and develop sustainably and that can contribute to societies around the world through its business activities. In the Biotechnology field, where Toyobo is focusing on IVD reagents and instruments as well as other products, overseas, mainly in the emerging countries, markets are forecast to expand at more than 10% annually. To expand sales in overseas markets, Toyobo has been considering alliances and M&A with overseas companies.
Given these circumstances, Toyobo acquired Spinreact, which has a network of dealers in approximately 90 countries around the world, covering not only Spain but also Africa, Central and South America, Europe, Asia, and elsewhere as well as an extensive lineup of IVD-related products that have been adapted for use in the emerging country markets.
![]() 「USCANNER® (E)」 (Urine Cell Analyzer) |
![]() 「FAD-GDH」 (Enzyme for At-Home Blood Sugar Sensors) |
2. Toyobo’s objectives in Acquiring Spinreact as a Wholly Owned Subsidiary
(1) To utilize Spinreact’s global sales network
In the field of IVD reagents and instruments, Toyobo will use Spinreact’s sales network to market its biochemical diagnostic agents, which are one of its strengths, as well as its urine analysis and gene analysis systems that are based on Toyobo’s advanced image processing and ultra high-speed PCR technology
(2) To expand its product lineup.
Toyobo will market Spinreact’s biochemical, immunology, and serology diagnostic reagents through Toyobo’s sales network in China and Southeast Asia.
(3) To secure a production base in Europe
Toyobo will draw on Spinreact’s production capabilities in Europe to develop its overseas bioproducts business.
3. Confirmed Acquisition Date: July 31, 2013
4. Outlook Going Forward
Going forward, Toyobo and Spinreact will use their bioproducts and sales networks to expand existing businesses. Next, the two companies will combine their biotechnologies to develop new products and expand into new markets.
5. Supplementary Information
(1)Outline of Spinreact S.A.
Location of the head office: Girona, Spain
Date of establishment: 1975
Representative: Josep Puig (General Manager)
Lines of business: Sales, manufacturing and developing of IVD reagents
For more information, contact:
The Toyobo Public Relations Group
pr_g@toyobo.jp
联系邮箱:kefu@labbase.net
版权与免责声明
- 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.labbase.net,违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
- 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。